businesspress24.com - Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
 

Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call

ID: 1313471

(firmenpresse) - MENLO PARK, CA -- (Marketwired) -- 10/28/14 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2014. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).



To participate, dial 1-888-771-4371 from the United States or +1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 38270277.

A replay will be available through November 18, 2014 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 38270277.



Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders. Korlym, a first generation competitive glucocorticoid (GR) antagonist, is the company''s first FDA-approved medication. The company has a Phase 1/2 trial of mifepristone for the treatment of triple-negative breast cancer and a portfolio of selective GR antagonists that competitively block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents for its selective GR antagonists.

For more information about Corcept please visit: .



CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals'' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cance
Bereitgestellt von Benutzer: Marketwired
Datum: 28.10.2014 - 15:05 Uhr
Sprache: Deutsch
News-ID 1313471
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

MENLO PARK, CA


Phone:

Kategorie:

Trials


Anmerkungen:


Diese Pressemitteilung wurde bisher 239 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Corcept Therapeutics to Announce Third Quarter Financial Results and Host Conference Call
"
steht unter der journalistisch-redaktionellen Verantwortung von

Corcept Therapeutics (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Corcept Therapeutics



 

Who is online

All members: 10 563
Register today: 2
Register yesterday: 2
Members online: 0
Guests online: 112


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.